Table 1.
Demographics, MRSA NS, procalcitonin, and immunosuppression in groups A, B, and C.
| Group A | Group B | Group C | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| +A | −A | Total | p value | +B | −B | Total | p value | +C | −C | Total | p value | |
| N | 28 | 84 | 112 | 59 | 147 | 206 | 56 | 171 | 227 | |||
|
| ||||||||||||
| Age | 0.111 | 0.361 | 0.611 | |||||||||
| Median | 60.0 | 68.0 | 66.0 | 71.0 | 68.0 | 69.0 | 68.0 | 69.0 | 68.0 | |||
|
| ||||||||||||
| Gender | 0.442 | 0.942 | 0.182 | |||||||||
| Female | 17 (60.7%) | 44 (52.4%) | 61 (54.5%) | 24 (40.7%) | 59 (40.1%) | 83 (40.3%) | 33 (58.9%) | 83 (48.5%) | 116 (51.1%) | |||
| Male | 11 (39.3%) | 40 (47.6%) | 51 (45.5%) | 35 (59.3%) | 88 (59.9%) | 123 (59.7%) | 23 (41.1%) | 88 (51.5%) | 111 (48.9%) | |||
|
| ||||||||||||
| MRSA NS | 0.433 | 0.343 | 0.673 | |||||||||
| Not done | 26 (92.9%) | 67 (79.8%) | 93 (83.0%) | 31 (52.5%) | 69 (46.9%) | 100 (48.5%) | 35 (62.5%) | 94 (55.0%) | 129 (56.8%) | |||
| Negative | 2 (7.1%) | 16 (19.0%) | 18 (16.1%) | 26 (44.1%) | 76 (51.7%) | 102 (49.5%) | 19 (33.9%) | 68 (39.8%) | 87 (38.3%) | |||
| Positive | 0 (0.0%) | 1 (1.2%) | 1 (0.9%) | 2 (3.4%) | 2 (1.4%) | 4 (1.9%) | 2 (3.6%) | 9 (5.3%) | 11 (4.8%) | |||
|
| ||||||||||||
| Procalcitonin | 0.372 | 0.522 | 0.892 | |||||||||
| Not done | 25 (89.3%) | 69 (82.1%) | 94 (83.9%) | 48 (81.4%) | 125 (85.0%) | 173 (84.0%) | 53 (94.6%) | 161 (94.2%) | 214 (94.3%) | |||
| Negative | 3 (10.7%) | 15 (17.9%) | 18 (16.1%) | 11 (18.6%) | 22 (15.0%) | 33 (16.0%) | 3 (5.4%) | 10 (5.8%) | 13 (5.7%) | |||
|
| ||||||||||||
| Immunosuppression | 0.912 | 0.812 | 0.912 | |||||||||
| No | 14 (50.0%) | 41 (48.8%) | 55 (49.1%) | 29 (49.2%) | 75 (51.0%) | 104 (50.5%) | 27 (48.2%) | 84 (49.1%) | 111 (48.9%) | |||
| Yes | 14 (50.0%) | 43 (51.2%) | 57 (50.9%) | 30 (50.8%) | 72 (49.0%) | 102 (49.5%) | 29 (51.8%) | 87 (50.9%) | 116 (51.1%) | |||
MRSA NS, methicillin-resistant Staphylococcus aureus nasal swab; 1Wilcoxon; 2chi-square; 3Fisher's exact.